Moderna Stock News

U.S. indices finished higher Tuesday following a lighter-than-expected PPI report and a drop in oil prices, which helped ease some inflation concerns. Investors continue to watch Russia-Ukraine develo

Resurgent worries about COVID-19 appear to be behind the stock's gains.

Pfizer''s CEO thinks a fourth booster is necessary, while Moderna''s president thinks an additional booster shot is only needed for some people.

On BioNTech's (BNTX) fourth-quarter earnings call, investors' focus is expected to be on the sales performance of Comirnaty, its COVID-19 vaccine developed in partnership with Pfizer.

Moderna (MRNA) starts dosing in an mRNA-based HIV vaccine study.

NEW YORK , March 15, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for JNJ, GME, DAL, MRNA, and ZM. … Full story available on Benzinga.com

Fauci Says More Vaccines Will Be Needed; "We''re Not Done With This" Authored by Steve Watson via Summit News, Health dictator Anthony Fauci declared Monday that Americans will need to take more COVID vaccines, just a day after the CEO of Pfizer proclaimed that a fourth shot is needed immediately. In an interview with CNBC , Fauci was asked how many more shots will be needed, and responded “The answer is: we don’t know. I mean, that’s it… it is likely that we’re not done with this when it comes to vaccines.” The comments dovetail with those of Albert Bourla, who said Sunday “It is necessary – a fourth boost – right now,” when asked about vaccines. The Pfizer head said “The protection that you are getting from the third [vaccine] is… not that good against infections, but doesn’t last very long but we are just submitting those data to the FDA and then we will see what the experts also will say outside Pfizer.” Pfizer CEO says a fourth COVID booster shot ''is necessary'' pic.twitter.com/tEaoGe3PO3 — VINnews (@VINNews) March 14, 2022 Bourla also told CNBC last week that Pfizer has officially notified the FDA of an upcoming application for a fourth vaccine: "After 3, 4 months it starts waning.

A new company has entered the public psychedelic markets, with an alternative drug-to-market approach. Using Real World Evidence trials, Albert Labs is expecting to legally provide psilocybin to patients in the UK much earlier than companies working with to get FDA approval. A former Moderna executive has taken a leadership position in MAPS, the largest nonprofit in the psychedelics space. In Oklahoma, a psilocybin decriminalization bill is headed to the state senate after getting approval from the state''s lower chamber. Albert Labs, Psychedelic Biotech Company Shares Now Available On Canadian Exchange Albert Labs, a British-Columbia-based biotech company, announced Thursday that it closed its private placement and that its shares will begin trading on the Canadian Securities Exchange (CSE). Albert Labs will trade under the ticker symbol “ABRT.” Read the full story… Former Moderna Vice President Joins Psychedelics Company In Phase 3 Trials For Ecstasy Michael Mullette, a former Moderna MNRA vice president is taking a senior leadership position in the MAPS Public Benefit Corporation, a biotech company in the psychedelics sector.

Amid concerns over how long the efficacy of mRNA COVID-19 vaccines would last, top executives at the two major developers of those vaccines have issued divergent views on the need…

Moderna (MRNA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in

The odds that Novavax wins U.S. Emergency Use Authorization for its vaccine should be pretty good.

Investors are excited about the potential of the company's new HIV vaccine.

U.S. indices finished lower Monday amid continued Russia-Ukraine uncertainty, as well as in anticipation of this week’s Fed decision. The Nasdaq composite finished lower by 2.04% to 12,581; The Inv